Man­u­fac­tur­ing woes de­rail a block­buster con­tender from Sanofi/Re­gen­eron. Who's next?

Sanofi wasn’t fret­ting need­less­ly over the up­com­ing FDA de­ci­sion re­gard­ing sar­ilum­ab.

The phar­ma gi­ant and its biotech part­ner Re­gen­eron $REGN an­nounced Fri­day af­ter­noon that the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER